GlycoMimetics Net Worth

GlycoMimetics Net Worth Breakdown

  GLYC
The net worth of GlycoMimetics is the difference between its total assets and liabilities. GlycoMimetics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of GlycoMimetics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. GlycoMimetics' net worth can be used as a measure of its financial health and stability which can help investors to decide if GlycoMimetics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in GlycoMimetics stock.

GlycoMimetics Net Worth Analysis

GlycoMimetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including GlycoMimetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of GlycoMimetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform GlycoMimetics' net worth analysis. One common approach is to calculate GlycoMimetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares GlycoMimetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing GlycoMimetics' net worth. This approach calculates the present value of GlycoMimetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of GlycoMimetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate GlycoMimetics' net worth. This involves comparing GlycoMimetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into GlycoMimetics' net worth relative to its peers.
To determine if GlycoMimetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlycoMimetics' net worth research are outlined below:
GlycoMimetics is way too risky over 90 days horizon
GlycoMimetics has some characteristics of a very speculative penny stock
GlycoMimetics appears to be risky and price may revert if volatility continues
GlycoMimetics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (37.88 B) with profit before overhead, payroll, taxes, and interest of 10 K.
GlycoMimetics currently holds about 60.24 M in cash with (31.1 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
GlycoMimetics has a frail financial position based on the latest SEC disclosures
GlycoMimetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlycoMimetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlycoMimetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
3rd of April 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow GlycoMimetics' market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.01 M.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlycoMimetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlycoMimetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlycoMimetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Jackson Scott Thomas over a month ago
Acquisition by Jackson Scott Thomas of 40000 shares of GlycoMimetics at 1.62 subject to Rule 16b-3
 
Invus Public Equities, L.p. over a month ago
Acquisition by Invus Public Equities, L.p. of 11451 shares of GlycoMimetics at 3.2419 subject to Rule 16b-3
 
Chinmaya Rath over three months ago
Acquisition by Chinmaya Rath of 250000 shares of GlycoMimetics at 3.11 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 260873 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.1917 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 61488 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.1821 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 55732 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.1828 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 164523 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.1884 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 286200 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.2004 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 63564 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.2162 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 756835 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.2209 subject to Rule 16b-3
 
Invus Public Equities, L.p. over six months ago
Disposition of 363949 shares by Invus Public Equities, L.p. of GlycoMimetics at 0.2353 subject to Rule 16b-3
 
Rock Edwin over six months ago
Acquisition by Rock Edwin of 115000 shares of GlycoMimetics at 0.2671 subject to Rule 16b-3
GlycoMimetics time-series forecasting models is one of many GlycoMimetics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GlycoMimetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

GlycoMimetics Earnings per Share Projection vs Actual

GlycoMimetics Corporate Executives

Elected by the shareholders, the GlycoMimetics' board of directors comprises two types of representatives: GlycoMimetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlycoMimetics. The board's role is to monitor GlycoMimetics' management team and ensure that shareholders' interests are well served. GlycoMimetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlycoMimetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Brian HahnCFO and Principal Accounting OfficerProfile
When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.